PCAC July 23, 2026 meeting will review BPC-157 and TB-500 for the 503A bulks list

The PCAC's published agenda for July 23, 2026 includes formal review of BPC-157 (body protection compound 157) and TB-500 (thymosin beta-4 fragment) for inclusion on the 503A compounding bulks list. Both molecules are currently in FDA Interim Category 2 — meaning 503A pharmacies CAN compound them under documented medical necessity, but a final categorization has not been issued.

What a favorable vote would change

If PCAC recommends inclusion and FDA accepts, BPC-157 and TB-500 would join the explicit 503A bulks list. Compounding pharmacies could then produce these peptides without per-patient medical-necessity justification. Practical effect: lower friction for prescribers, broader pharmacy capacity, more transparent pricing.

What the lobby positions look like

The American Pharmacists Association (APhA) and the International Academy of Compounding Pharmacists (IACP) have signalled support for inclusion citing a decade-plus of safe compounding history. Concern from FDA staff has focused on the absence of US human RCT evidence — both peptides have substantial animal-model data and Eastern European clinical use, but Phase 2/3 US RCTs have not been published.

What we will be tracking

Pre-meeting docket: comment letters submitted to the docket through July 9. Vote outcome: roll-call recorded at the meeting. FDA acceptance: typically 60-180 days post-meeting if the agency follows the recommendation; longer if it diverges.